


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Roth et al.) Art Unit: 1625
Serial No. : 09/678,682) Examiner: Morris, P.
Filed : October 3, 2000)
For : SUBSTITUTED INDOLINES WHICH INHIBIT RECEPTOR TYROSINE
KINASES
Docket No. : 5/1275
Confirmation No.: 6798

Certificate of Transmission under 37 CFR 1.8
I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office (attn: TC 1600 at 703-872-9306) on March 26, 2002.

By: Alan Stempel
Reg. No. 28,991

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO OFFICE ACTION


Sir:

In response to the Office action mailed on February 27, 2002, please enter the following elections.

ELECTIONS

Applicants hereby elect to prosecute claims directed to the invention of Group I, that is, the invention of claims 1-7, drawn to compounds and compositions, classified in classes 540, 544, 546 and 548, various subclasses.

Applicants further elect the following single disclosed species: 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone. The elected species is disclosed on page 226 as compound No. (473) and has the following structure:



The elections are made ~~with~~ without traverse.

Respectfully submitted,

Alan Stempel
Attorney for Applicant(s)
Reg. No. 28,991

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 798-4868